Fraud Unearthed at Ranbaxy Bata Mandi ,Paonta Sahib plant

Discussion in 'Ranbaxy' started by Anonymous, Mar 23, 2008 at 10:33 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    If you read any of the news coverage you would know that Daiichi doesn't have an "out". They're stuck with Ranbaxy, for better or worse.

    And if you think that Malvinder didn't disclose the nature of our FDA inspection and DOJ investigation issues to Daiichi before the deal, you are naive.
     

  2. Anonymous

    Anonymous Guest

    Actually Daiichi wants to use Ranbaxy facilities in India for making cheap generic products for Japanese market. The market is just opening up to Generic and there is huge potentiality.Being a Japanese company they actually will have edge. They are least bothered on FDA clearence and US generic market. Just see how they forced Ranbaxy to withdraw Lipitor case.
    Increasingly US generic market will have less importance for Ranbaxy.
     
  3. Anonymous

    Anonymous Guest

    Hey mam,

    Its not that easy to make cheap generics for Japan .The company who has bad history of market complaints , recalls in other markets will be wiped out if they enter Japan with quality standards they call as Quality .They are in big shit now .Japan is the most tough market for Pharma .If Japs sit here and do it , its a different story.Dewas plant tried with Voglibose tablets to Japan and the whole lots were withdrawn and NPI Japan threatened to quit the JV due to that .All this shit wasgoing to hit the roof and Malav smartly sold his stake .Its that simple guys...
     
  4. Anonymous

    Anonymous Guest

    Its not being niave its knowning Malav's character.

    Even if Diiachi was dumb enough not to negotiate an out into the contract "fraud" is always an out in any contract.

    Diiachi's primary motivation is to obtain manufacturing capacity to support the Japanese market but I doubt they would pay $4.4 B for a majority stake just for that purpose. And if you know anything about the Japanese market you will know that it will be more difficult there to get approvals than the US market.

    Sleaze balls in product development, regulatory, and manufacturing will not survive.
     
  5. Anonymous

    Anonymous Guest

    The US market will have less importance for Ranbaxy because the senior people there didn't have the intellect and integrity to compete effectively.

    When Ranbaxy came to the US they had a hudge cost advantage and they blew it. All they had to do was copy (the only thing they are good at) and follow the very clear rules for product development and manufacturing. Now they are doing more and more manufacturing in the US giving away whatever remaining advantage they may have had.

    But they thought they could put the crap onto the US market that they foist upon the citizens of India and unfortunately because for so many years the FDA has been a paper tiger they got away with it. Now these visionless idiots find themselves one of the poster children for the FDA's enforcement of substandard foreign manufacturers.

    Maybe someone can tell me why the citizens of India are not outraged; they have been exposed to Ranbaxy's low quality products for a lot longer than the US market.
     
  6. Anonymous

    Anonymous Guest

    One senior ex-Ranbaxy pharma development fraud has joined a domestic company. The company had a recall of 6 lacs vials of injection. Poor development shows. poor company was doing good in domestic and this ranbaxy fraud is leading them to problems. The company is expected to have more recalls from Europe.
    The US FDA has hold its approval inspite of the inspection that happened six months back. it is expected that there will a inspection of this facility agin jointly by FDA and European agency. Company's beware of taking senior ranbaxy people especially in pharma they are all frauds!!
     
  7. Anonymous

    Anonymous Guest

    Which is this Indian company? We got to read about a recall from france from this company. This came in Economic Times. I was shocked to see the response of the company. They said that value of recall material is fraction of the turnover. They will face the heat when UK agency's will come to their facility. All exports done till today will have to be recalled.
    how has Pharma research person contributed to this recall. Can anyone tell me.
     
  8. Anonymous

    Anonymous Guest

    Re: Recalls and more recalls-Now Alkem

    Looks like this is Alkem. One ex-Ranbaxy has joined them recently. He is the same guy who got into limelight with Cipro OD but later on was found to be a fake! He was asked to leave Ranbaxy by Dr. Sen once Dr. Sen rejoined Ranbaxy. He is the person who is responsible along with Parekh to take paonta facility to shits. Both led to disaster at paonta- one from manufacturing adjustments and the other one with fake formulations.
     
  9. Anonymous

    Anonymous Guest

    Not only pharma Head, we heard the new Quality head of Alkem also is fraud. All problems of ranbaxy was created in their times only. Alkem beware you are going to go to dogs.
     
  10. Anonymous

    Anonymous Guest

    Re: Recalls and more recalls-Now Alkem

    Take a crash course in pharma man!! The said recalled injection is sterile API fill , no formulation development here. Take a life and don’t shit your personal grudges in this forum. It is perhaps purely a manufacturing/QA related issue rather that development.
     
  11. Anonymous

    Anonymous Guest

    Re: Alkem recall

    Some idiot guy also joined Alkem,who was sacked from DRL for manipulating datas in their oncology plant.Hence, unsuccessful inspection.He was sacked immediately.
    He then became a property dealer for a while.He was earlier commented by his ex-employer as manipulator in Ranbaxy days.And was chuked out.
    Now again he has commited blunder: Rather than justifying his quality standards in ET he was replying on commercial issues. How PR is handled in Alkem: this is the right example. OR do they even know PR and Corp. Comm.
    There are still breads available for such FRAUDS in Indian Pharma industry.
    Also heard about him protecting one of the plant head in theft and financial manipulation.
     
  12. Anonymous

    Anonymous Guest

    Hey
    Some more fakes are still with Ranbaxy. Abha Pant ,Chandrasekhar etc tops the list. Actually , Ranbaxy R&D is the breeding centre of Politicians. They have given more politicians than products
     
  13. Anonymous

    Anonymous Guest

    You are right. Many more are still there. Tauseef, Parekh and many more.
     
  14. Anonymous

    Anonymous Guest

    Re: Recalls and more recalls-Now Alkem

    Hahaha - I presume you're not inciting someone to commit murder and instead meant to say GET A LIFE!

    Though it is a Freudian slip, given the quality (or lack thereof) of drugs this company is accused of producing.
     
  15. Anonymous

    Anonymous Guest

    Re: Recalls and more recalls-Now Alkem

    Infact one more ex-Ranbaxy guy is having his second stint in Alkem. He has been sacked following the DRL's oncology's plant unsuccessful FDA inspection.He is a great manipulator and was even questioned by Ranbaxy's Owner as express manipulator. He was even commenting on Alkem's recall. Although the label claim is BP he said its passing in USP.This how he defends quality systems and was answering the commercial issues also. Does he understand any bit of commercial. AND What about PLIVA's quality complaints. He manipulated their filings also. NOW Alkem is running DUAL technology.The TWOSOME.
     
  16. Anonymous

    Anonymous Guest

    Re: Recalls and more recalls-Now Alkem


    Please read the news from top most pharma journal of the world
    Three lakh injections are recalled by Alkem from worldwide
    New Delhi,India
    09 Jul 2008

    Alkem is recalling approximately 3 lakh injection from a number of overseas markets. Source of the drug was Indian distribution firm Synergia Life Sciences for supply France, African markets and a few global NGOs.

    It was told to Alkem that the drug had failed. Alkem said that the drug had passed the test when they tested it in their laboratory then the drugs were tested again in European laboratories and found the adverse result. Then company decided to recall the product.

    Synergia is a business partner of CSEP. This is a part of multi-million dollar pharmaceutical conglomerate based in France. The company claims that the injection has passed the British Pharmacopoeia standards, according to supply agreement and the labels the drugs. Some parts of the US pharmacopoeia are used to claim that the drug has not failed. It was found that the recall would have very little as the value of the order is 0.011% of its Rs 1,000 crore sales. Also there is 2% variation between drugs tested in different laboratories.
     
  17. Anonymous

    Anonymous Guest

    Re: Alkem recall

    NEW DELHI: Alkem is recalling six batches, or around three lakh, of ampicillin injection from several overseas markets after discovering that the drugs did not contain the specified dosage. The drug was sourced by an Indian distribution firm Synergia Life Sciences to supply France, African markets and a few global NGOs.

    In October last year, Alkem was told that the drug had failed. However, Alkem said the drug passed the test when the company independently conducted tests in its own laboratories. Subsequently, the drugs were re-tested in three more European laboratories, including AFFSAPS, (the French equivalent of USFDA) which also showed adverse results. The Indian company finally decided to recall its product last month but maintains that the drugs still pass the US standards.

    “Though Alkem is on very sure grounds with respect to the quality of the consignment, we had taken a decision to recall the consignment, “ said Alkem president, corporate quality assurance, Dr K N Singh. Alkem alleged that Synergia and CSEP (Centre Specialities Export Pharma) was trying to malign the company after it (Alkem) decided to tap these markets on its own. ”We feel that CSEP is coercing us into continuing commercial relations with it by bringing up this matter regarding. It’s a minor variation in assay (potency),“ Dr Singh added.

    Synergia is a strategic business partner of CSEP, which is a part of a multi-million dollar pharmaceutical conglomerate based in France. Synergia CEO Tobby Simon however said that the Mumbai-based company was using the contractual loss to cover up the failure and its refusal to take responsibility.

    “According to the supply agreement and the labels in the drugs, the company claims that the injection has passed the British Pharmacopea standards. They are conveniently using parts of the US Pharmacopoeia to claim that the drug has not failed, “ Mr Simon added.

    Alkem has said that the assay (potency) value in the samples with CSEP was in the range of 91 to 93% as against the British standard of 95–105%. Even the US standards allows for the assay values to be in the range of 90 to 115%.
    He, however, said that the recall would have little implication on the company as the value of the order is 0.011% of its Rs 1,000 crore sales.

    Also, as per the globally analytical norms, there is usually a 2% variation between drugs tested in different laboratories.
     
  18. Anonymous

    Anonymous Guest

    Re: Recalls and more recalls-Now Alkem

    http://www.pharmalot.com/2008/07/con...y-allegations/
    Please go to the link above friend and tell the world that it is all manipulations at the devlopment stage. bioequivalence studies are not managed by QA!
    All current and ex Formulation heads of Ranbaxy-pack your bags you are going to be screwed by Malvinder.
     
  19. Anonymous

    Anonymous Guest

    See http://oralstemcell.com/products/antibiotics/erythromycin/order/
     
  20. Anonymous

    Anonymous Guest

    The FDA needs to come in a close this company. Everything they do goes against compliance. The New Jersey offce needs to be the first one closed and take AA back to India where he belongs. Sounds ike more people who know what is going on illegally on the inside need to come forward and expose this company for who they really are.